Noninvasive Imaging Deemed Adequate in Prediction of MACE

This article originally appeared here.
Share this content:
Noninvasive Imaging Deemed Adequate in Prediction of MACE
Noninvasive Imaging Deemed Adequate in Prediction of MACE

WEDNESDAY, March 15, 2017 (HealthDay News) -- Computed tomography (CT) angiography and CT myocardial stress perfusion imaging have similar prediction of two-year major adverse cardiovascular events (MACE) as combined invasive coronary angiography (ICA) and stress single photon emission CT myocardial perfusion imaging, according to a study published online March 14 in Radiology.

Marcus Y. Chen, M.D., from the U.S. National Institutes of Health in Bethesda, Md., and colleagues compared the prognostic importance of combined CT angiography and CT myocardial stress perfusion imaging with combined ICA and stress single photon emission CT myocardial perfusion imaging for 381 patients clinically referred for ICA.

The researchers found that 51 of 379 patients (13.5 percent) had a MACE. The two-year MACE-free rates were 94 percent negative for coronary artery disease (CAD) versus 82 percent positive for CAD for combined CT angiography and CT perfusion findings. These values were similar to combined ICA and single photon emission CT findings of 93 percent negative for CAD versus 77 percent positive for CAD (both P < 0.001). For the identification of MACE at two-year follow-up, the area under the receiver operating characteristic curve was similar for combined CT angiography and CT perfusion and for combined ICA and single photon emission CT (68 and 71, respectively; P = 0.36).

"Combined CT angiography and CT perfusion enables similar prediction of two-year MACE, late MACE, and event-free survival similar to that enabled by ICA and single photon emission CT," the authors write. "A purely noninvasive anatomic and physiologic assessment via CT angiography and myocardial perfusion is adequate to identify patients with a MACE at two-year follow-up in symptomatic patients suspected of having CAD."

Several authors disclosed financial ties to medical device companies, including Toshiba Medical Systems.

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Single-Payer Health System Bill Moves Forward in California

Single-Payer Health System Bill Moves Forward in California

Not yet clear where money for the single-payer system would come from

Regorafenib Approved for Hepatocellular Carcinoma

Regorafenib Approved for Hepatocellular Carcinoma

It is the first approved treatment for HCC in almost a decade

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Three Anti-VEGF Treatments Effective for Diabetic Retinopathy

Rates of worsening low in patients receiving aflibercept, bevacizumab, or ranibizumab

is free, fast, and customized just for you!

Already a member?

Sign In Now »